$BXLT (Baxalta Incorporated)

$BXLT {{ '2015-10-29T12:51:31+0000' | timeago}} • Webcast

$BXLT said, it's building a solid track record with a range of meaningful milestone achievements toward its goal of launching 20 new products by 2020 with a pipeline of promising late-stage assets, novel mechanisms and disruptive technologies.

$BAX {{ '2016-05-24T20:35:48+0000' | timeago}} • Announcement

$BAX announced final results of its offer to exchange up to 13.36MM common shares of $BXLT owned by $BAX for its common shares. The exchange offer expired on May 18. All 13.36MM $BXLT common shares owned by $BAX will be distributed to $BAX stockholders, who validly tendered their shares, and $BAX will not hold any shares of $BXLT.

$BAX {{ '2016-05-17T12:48:49+0000' | timeago}} • Announcement

Provider of renal & hospital products $BAX announced the final exchange ratio in connection with its earlier announced offer to exchange up to 13,360,527 shares of common stock of $BXLT currently owned by $BAX for its shares. For each share of $BAX, it will deliver 1.1591 shares of $BXLT common stock to or at the direction of tendering stockholder.

$BXLT {{ '2016-04-28T15:51:59+0000' | timeago}} • Announcement

$BXLT, which is set to be acquired by UK's Shire Plc, said the company will not be providing financial guidance for the second quarter or full-year 2016, and previously-issued guidance for Baxalta as a standalone entity is no longer applicable.

$BXLT {{ '2016-04-28T15:48:22+0000' | timeago}} • Announcement

Biopharmaceutical major $BXLT reported a 14% jump in 1Q16 revenue, but quarterly profit fell on higher costs. The company, focused on hemophilia treatment, reported earnings of $145MM, or $0.21 per share, down from $272MM, or $0.38 per share a year ago. Revenue rose to $1.55Bil. Expenses rose by 36%.

$BAX {{ '2016-04-21T20:22:22+0000' | timeago}} • Announcement

$BAX said it has commenced an offer to exchange up to 12.8MM shares of $BXLT common stock that are currently owned by $BAX, which represents about 1.9% of outstanding common stock of $BXLT, for shares of $BAX common stock that are validly tendered and not validly withdrawn in the exchange offer.

$BAX {{ '2016-04-05T05:16:53+0000' | timeago}} • Announcement

After approval from Japan's Ministry of Health, $BXLT transferred the marketing authorization from $BAX to Baxalta Japan. In the US, ADYNOVATE is licensed for use in adult and adolescent patients and is under regulatory review for use in pediatric and surgical settings. ADYNOVATE is also under regulatory review in Canada, Switzerland and Europe.

$BXLT {{ '2016-04-05T05:15:57+0000' | timeago}} • Announcement

$BXLT said the Japan's Ministry of Health, Labour and Welfare has approved ADYNOVATE, an extended circulating half-life recombinant Factor VIII treatment, for patients 12 years and older with hemophilia A. ADYNOVATE leverages pegylation technology reducing the speed at which it is cleared from the blood, thus resulting in increased half-life.

$BXLT {{ '2016-04-04T19:31:42+0000' | timeago}} • SEC

$BXLT's capital expenditures for 2015 increased to $1.2Bil from $970MM last year. This increase was driven by several projects aimed at improving manufacturing capacity for the company's products, including increased expenditures associated with the construction of the Covington, Georgia manufacturing facility.

$BXLT {{ '2016-04-04T19:30:31+0000' | timeago}} • SEC

$BXLT's net cash used in investing activities for 2015 increased to $2.29Bil from $501MM last year. This increase was due primarily to increased cash outflows for acquisitions and a 2014 cash inflow of $640MM from the sale of the commercial vaccines business.

$BXLT {{ '2016-04-04T19:27:29+0000' | timeago}} • SEC

$BXLT's net cash provided by operating activities for 2015 decreased to $799MM from $1.37Bil last year. This was due to lower income excluding certain non-cash charges and gains. Sales growth and resulting gross profit growth was more than offset by increased expenses, including from separation costs and increased investments in the R&D pipeline.

$BXLT {{ '2016-04-04T19:24:43+0000' | timeago}} • SEC

$BXLT's gross margin for 2015 rose to 61.2% from 59% last year. Excluding impact of special items, gross margin in 2015 reflects favorable impact from FX rate fluctuations and hedging activities, benefits from increased sales of higher-margin products such as ADVATE and FEIBA, and a favorable contribution from ONCASPAR sales.

$BXLT {{ '2016-04-04T19:06:27+0000' | timeago}} • SEC

Biopharma company $BXLT's global net sales for 2015 rose by 3% from last year. Excluding impact of foreign currency exchange rate fluctuations, net sales increased by 11%. Sales in the United States grew 10%, while international sales slid by 4%. Excluding impact of foreign currency exchange rate fluctuations, international sales grew 13%.

$BXLT {{ '2016-02-26T11:50:17+0000' | timeago}} • Announcement

$BXLT said it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

$BXLT {{ '2016-02-16T12:32:42+0000' | timeago}} • Announcement

For 1Q16, $BXLT expects pro forma sales growth, excluding foreign currency, of 8-9%. Including foreign currency, company expects pro forma sales to grow 4-5%. Adjusted diluted EPS, before special items, is expected to be $0.44-0.46. 1Q16 outlook excludes about $0.03 per diluted share of intangible asset amortization expense.

$BXLT {{ '2016-02-16T12:30:48+0000' | timeago}} • Announcement

$BXLT's 4Q15 sales rose 5% to $1.8Bil. US sales rose 13%. International sales fell 7%; excluding foreign currency international sales rose 8%. Company's largest business, Hematology, sales rose 6% and Immunology sales rose 8%. Oncology sales were $53MM, reflecting sales from the acquisition of ONCASPAR, a treatment for lymphoblastic leukemia.

$BAX {{ '2016-02-16T12:28:21+0000' | timeago}} • Announcement

Biopharma company $BXLT reported 4Q15 net income of $95MM or $0.14 per diluted share, including net after-tax special items of $292MM, mainly for intangible asset amortization and expenses associated with $BXLT's separation from $BAX. Adjusted net income was $387MM or $0.57 per diluted share versus outlook of $0.55-0.57 per diluted share.

$BXLT {{ '2016-01-11T14:04:11+0000' | timeago}} • Announcement

The offer value, as of $SHPG's Jan. 8, 2016 closing ADS price, represents a premium of approx. 37.5% to $BXLT's unaffected share price on Aug. 3, 2015. This will provide $BXLT shareholders with approx. 34% ownership in the combined company. The transaction has been approved by BoD of both companies and expect the transaction to close mid-2016.

$BXLT {{ '2016-01-11T14:03:01+0000' | timeago}} • Announcement

Specialty biopharmaceutical company $SHPG said it is buying $BXLT. Under the agreement terms, $BXLT shareholders will receive $18 in cash and 0.1482 Shire ADS per Baxalta share. Based on $SHPG's closing ADS price on Jan. 8, 2016, this entails a total current value of $45.57 per $BXLT share, representing an aggregate consideration of approx. $32Bil.

$BXLT {{ '2015-12-21T12:38:50+0000' | timeago}} • Announcement

$BXLT and $MNTA announced the initiation of a separate pivotal clinical trial of M923 in chronic plaque psoriasis in Oct.r 2015. $BXLT and $MNTA are targeting a first regulatory submission in 2017 and a first commercial launch as early as 2018.

$BXLT {{ '2015-12-21T12:37:46+0000' | timeago}} • Announcement

$BXLT and $MNTA say this study also evaluated safety, tolerability and immunogenicity following single doses of M923 given by injection. The safety profile and immunogenicity were also found to be comparable. A total of 324 healthy volunteers were enrolled in the study.

Recent Transcripts

OPB (Opus Bank)
Monday, July 24 2017 - 3:00pm
ARNC (Arconic Inc.)
Monday, July 24 2017 - 2:00pm
TMUS (T-Mobile US, Inc.)
Wednesday, July 19 2017 - 8:30pm
LTXB (LegacyTexas Financial Group Inc.)
Wednesday, July 19 2017 - 1:00pm
EBS (Emergent BioSolutions, Inc.)
Thursday, May 4 2017 - 9:00pm
NVO (Novo Nordisk A/S)
Thursday, May 4 2017 - 12:15pm
SQ (Square, Inc.)
Wednesday, May 3 2017 - 9:00pm
FIT (Fitbit Inc.)
Wednesday, May 3 2017 - 9:00pm
NVO (Novo Nordisk A/S)
Wednesday, May 3 2017 - 11:00am
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
SHPG (Shire plc)
Tuesday, May 2 2017 - 1:00pm
SHOP (Shopify Inc.)
Tuesday, May 2 2017 - 12:30pm
AMD (Advanced Micro Devices, Inc.)
Monday, May 1 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, April 27 2017 - 1:00pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
BAX (Baxter International Inc.)
Wednesday, April 26 2017 - 12:30pm
ARNC (Arconic Inc.)
Tuesday, April 25 2017 - 9:00pm
TMUS (T-Mobile US, Inc.)
Monday, April 24 2017 - 8:30pm

AlphaGraphics you may like